Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 4, 2013, Pages 313-320

  Gonzalez Angulo, A M ^a   Blumenschein, G R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarker; Breast cancer; PI3K Akt mTOR; Selection; Sensitivity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; AZD 5363; BIOLOGICAL MARKER; BMK 120; BUPARLISIB; BYL 719; CAPECITABINE; DALOTUZUMAB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GDC 0980; GLYCOGEN SYNTHASE KINASE 3BETA; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NERATINIB; PACLITAXEL; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PROTEIN BAD; PROTEIN KINASE B INHIBITOR; RIDAFOROLIMUS; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXO; TRASTUZUMAB; TUBERIN; UNCLASSIFIED DRUG; XL 147;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SCINTISCANNING; DRUG RESPONSE; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84875549182     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.11.002     Document Type: Review

References (73)

1. Agarwal R., Carey M., Hennessy B., Mills G.B. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010, 11:615-628.
2. Miller T.W., Perez-Torres M., Narasanna A., Guix M., Stal O., Perez-Tenorio G., et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009, 69:4192-4201.
3. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
4. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
5. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656.
6. Nahta R., O'Regan R.M. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 2010, 10(Suppl. 3):S72-S78.
7. Fisher B., Redmond C., Brown A., Wickerham D.L., Wolmark N., Allegra J., et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983, 1:227-241.
8. Fisher B., Redmond C., Brown A., Wolmark N., Wittliff J., Fisher E.R., et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981, 305:1-6.
9. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
10. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287.
11. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
12. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 2010, 1:530-543.
13. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
14. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
15. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
16. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
17. Kang S., Bader A.G., Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005, 102:802-807.
18. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
19. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
20. Meyer D.S., Brinkhaus H., Muller U., Muller M., Cardiff R.D., Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011, 71:4344-4351.
21. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
22. Lopez-Knowles E., O'Toole S.A., McNeil C.M., Millar E.K., Qiu M.R., Crea P., et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
23. Gonzalez-Angulo A.M., Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera J.A., et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011, 10:1093-1101.
24. Hernandez-Aya L.F., Gonzalez-Angulo A.M. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011, 16:404-414.
25. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
26. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
27. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
28. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
29. Loi S., Michiels S., Lambrechts D., Salgado R., Sirtaine N., Fumagalli D., et al. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): results from the FinHER trial. J Clin Oncol 2012, 30(Suppl.). [abstr. 507].
30. Weigelt B., Downward J. Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol 2012, 2:109.
31. O'Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010, 16:3670-3683.
32. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68:8022-8030.
33. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009, 106:22299-22304.
34. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
35. Sanchez C.G., Ma C.X., Crowder R.J., Guintoli T., Phommaly C., Gao F., et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011, 13:R21.
36. Sangai T., Akcakanat A., Chen H., Tarco E., Wu Y., Do K., et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. J Clin Oncol 2012, 30(Suppl.). [abstr. 1054].
37. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30:3222-3233.
38. Kwei K.A., Baker J.B., Pelham R.J. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS One 2012, 7:e46518.
39. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3:e3065.
40. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., et al. Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor. Mol Cancer Ther 2012, 11:317-328.
41. Meric-Bernstam F., Akcakanat A., Chen H., Do K.A., Sangai T., Adkins F., et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012, 18:1777-1789.
42. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
43. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009, 106:19503-19508.
44. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., DeBeaumont R., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008, 105:13057-13062.
45. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
46. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
47. Zhao J.J., Cheng H., Jia S., Wang L., Gjoerup O.V., Mikami A., et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 2006, 103:16296-16300.
48. Zhao L., Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008, 105:2652-2657.
49. Janku F., Wheler J.J., Westin S.N., Moulder S.L., Naing A., Tsimberidou A.M., et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012, 30:777-782.
50. Juric D., Baselga J. Tumor genetic testing for patient selection in Phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 2012, 30:765-766.
51. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866.
52. Mayer I.A., Gupta Abramson V., Balko J.M., Isakoff S.J., Kuba M.G., Sanders M., et al. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER-metastatic breast cancer (MBC). J Clin Oncol 2012, 30(Suppl.). [abstr. 510].
53. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., et al. Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012, 30:282-290.
54. von Hoff D., LoRusso P.M., Demetri G.D., Weiss G.J., Shapiro G.I., Ramanathan R.K., et al. A Phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol 2011, 29(Suppl.). [abstr. 3052].
55. Moreno Garcia V., Baird R.D., Shah K.J., Basu B., Tunariu N., Blanco M., et al. A Phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 2011, 29(Suppl.). [abstr. 3021].
56. Oliveira M., Navarro A., De Mattos-Arruda L., Sánchez-Ollé G., Bellet M., Balmaña J., et al. PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2012, 30(Suppl.). [abstr. 509].
57. US National Institutes of Health.; [accessed October 2012]. http://www.clinicaltrials.gov.
58. Loboda A., Nebozhyn M., Cheng C., Vessey R., Huang P., Dai H., et al. Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther 2009, 86:92-96.
59. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
60. O'Reilly T., McSheehy P.M. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010, 3:65-79.
61. Squillace R.M., Miller D., Cookson M., Wardwell S.D., Moran L., Clapham D., et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 2011, 10:1959-1968.
62. Ellard S.L., Clemons M., Gelmon K.A., Norris B., Kennecke H., Chia S., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27:4536-4541.
63. Crouthamel M.C., Kahana J.A., Korenchuk S., Zhang S.Y., Sundaresan G., Eberwein D.J., et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009, 15:217-225.
64. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
65. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
66. Tolcher A.W., Yap T.A., Fearen I., Taylor A., Carpenter C., Brunetto A.T., et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009, 27(Suppl.). [abstr. 3503].
67. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324.
68. Loboda A., Nebozhyn M., Klinghoffer R., Frazier J., Chastain M., Arthur W., et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics 2010, 3:26.
69. Janku F., Broaddus R., Bakkar R., Hong D.S., Stepanek V.M.T., Naing A., et al. PTEN assessment and PI3K/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations. J Clin Oncol 2012, 30(Suppl.). [abstr. 10510].
70. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664.
71. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28:2777-2783.
72. Middleton L.P., Price K.M., Puig P., Heydon L.J., Tarco E., Sneige N., et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009, 133:775-780.
73. Dybdal N., Leiberman G., Anderson S., McCune B., Bajamonde A., Cohen R.L., et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93:3-11.